Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2010
Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8.
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00043069 (Osteoporosis Prevention in Prostate Cancer Patients Receiving Androgen Ablation Therapy), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Osteoporosis Prevention in Prostate Cancer Patients Receiving Androgen Ablation Therapy: A Phase III Randomized, Placebo-Controlled, Double-Blind Study
Who cites it
10 citing papers in PubMed.
- Bone Health Management in Men Commencing Androgen Deprivation Therapy for Prostate Cancer and Women Commencing Anti-Oestrogen Therapy for Breast Cancer.Cancer medicine · 2025Review
- Systematic comparison of Mendelian randomisation studies and randomised controlled trials using electronic databases.BMJ open · 2023Article
- Bone-modifying agents for bone loss in patients with prostate cancer receiving androgen deprivation therapy; insights from a network meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation.Oncotarget · 2017Review
- Prognostic significance of baseline fatigue for overall survival: A patient-level meta-analysis of 43 oncology clinical trials with 3915 patients.Trends in cancer research · 2017Article
- Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.European journal of endocrinology · 2015Review
- Antiresorptive therapy in the management of cancer treatment-induced bone loss.Current osteoporosis reports · 2015Review
- The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment.Nutrients · 2014Review
- Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review.The oncologist · 2012Review
- Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.Clinical Medicine Insights. Oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeThe purpose of this study is to test the ability of risedronate and estradiol, alone or in combination, to prevent bone loss associated with androgen deprivation therapy in men with prostate cancer. MATERIALS AND
methodsThis is a randomized placebo-controlled trial of risedronate and estradiol, alone or in combination, in men with prostate cancer receiving androgen deprivation therapy. The primary outcome was change in hip bone mineral density at 1 year.
resultsNo statistical difference was found among the groups for bone mineral density changes. The only side effects of note were increased gynecomastia and breast tenderness associated with estrogen therapy. The study was limited by poor accrual and subsequent lack of statistical power.
conclusionsMen receiving androgen deprivation therapy for prostate cancer are at risk for bone loss and should receive appropriate bone density monitoring and preventive advice about calcium, vitamin D, exercise, and fall prevention. Prescription drugs proven in this patient population should be used when the risk of fracture is high.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.